



RECEIVED

OCT 12 2000

PATENT
Attorney's Matter No. 1688/2900 4239-50420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Art Unit: 1646

Meltzer et al.

Application No. 09/125,635

Filed: August 21, 1998

For: AIB1, A NOVEL STEROID RECEPTOR
COACTIVATOR

Examiner: N. Basi

Date: October 2, 2000

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 2, 2000 as First Class Mail in an envelope addressed to: BOX NON-FEE AMENDMENT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C.

20231.

William D. Noonan, M.D.
Attorney for Applicant

C/12
10/17/02

RESPONSE TO RESTRICTION REQUIREMENT

TO THE COMMISSIONER FOR PATENTS
Washington, D.C. 20231

This is a response to the Office action dated August 30, 2000. A one month period for response was set, making a response due on or before October 2, 2000.

Please amend the application as follows:

In the claims:

Ci 23. (Amended), The method of claim [21] 22, wherein the aberrantly proliferating cell is a steroid hormone-responsive cancer cell.

Remarks

The applicants are grateful to the Examiner for pointing out the typographical error in claim 23. This error has been corrected, and claim 23 now properly depends from claim 22, where antecedent basis for "aberrantly proliferating cell" may be found.

Claims 12-45 and 47-65 are pending in the present application. As part of a lack of unity of invention objection, the Examiner divided the claims into eight groups. Group I, claims 55-65, is drawn to polynucleotides encoding the AIB1 polypeptide, cells comprising the polynucleotide, and DNA hybridizing to the polynucleotide. Group II, claims 12-13, is drawn to a substantially purified